3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
CNS
3
Endocrine
2
Plasma cell
1
NET
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
14
Brain Neoplasms
6
Ovarian Neoplasms
4
Melanoma
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasms, Second Primary
2
Fallopian Tube Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms, Male
1
Astrocytoma
1
Interventions
pembrolizumab
29
Gemcitabine
16
Cyclophosphamide
14
Nivolumab
12
Carboplatin
12
Capecitabine
11
Trastuzumab
9
Paclitaxel
9
Magnetic Resonance Spectroscopy
8
Irinotecan
8
Bevacizumab
8
Albumin-Bound Paclitaxel
8
130-nm albumin-bound paclitaxel
8
olaparib
7
fludarabine
7
Docetaxel
7
spartalizumab
6
aldesleukin
6
Drug Therapy
6
Cisplatin
6
durvalumab
5
atezolizumab
5
Standard of Care
5
Specimen Handling
5
Oxaliplatin
5
Biopsy
5
sargramostim
4
palbociclib
4
niraparib
4
enzalutamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Temozolomide
×
Breast
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled